Back to results
US 12,673,093 B2Granted
Method and composition for treating arginase 1 deficiency
AssigneeImmedica Pharma AB
InventorsScott W. Rowlinson, Anthony G. Quinn, Ann Lowe, David Lowe
Life of this patent
Estimating the term…
Abstract
A method and composition to treat a subject with arginase 1 (ARG1) deficiency (ARG1-D) and to rapidly reduce the levels of at least one of arginine and/or a guanidino compound in the subject.
Claims22
A method for reducing a plasma level of at least one compound selected from the group consisting of:
- arginine, N-α-acetylarginine (NAArg), argininic acid (ArgA), α-keto-δ-guanidinovaleric acid (GVA), guanidinoacetic acid (GAA), to a normal level in a subject with Arginase 1 (ARG1) deficiency (ARG1-D) comprising administering to the subject a composition comprising a therapeutically effective amount of a pegylated arginase, wherein the pegylated arginase is administered intravenously initially at a dosage of about 0.1 mg/kg, and weekly thereafter either subcutaneously or intravenously at a dosage of about 0.01 mg/kg to about 1.00 mg/kg.
A method for reducing a plasma level of at least one compound selected from the group consisting of:
- arginine, N-α-acetylarginine (NAArg), argininic acid (ArgA), α-keto-δ-guanidinovaleric acid (GVA), guanidinoacetic acid (GAA), to a normal level in a subject with Arginase 1 (ARG1) deficiency (ARG1-D) comprising administering to the subject a composition comprising a therapeutically effective amount of a pegylated arginase, wherein the pegylated arginase is administered subcutaneously initially at a dosage of about 0.1 mg/kg, and weekly thereafter either subcutaneously or intravenously at a dosage of about 0.01 mg/kg to about 1.00 mg/kg.
Dependencies are inferred from the claim text.